Objective: To investigate the impact of tuberculosis-associated immune reconstitution inflammatory syndrome (TB-IRIS) upon immunological recovery and the T-cell compartment after initiation of TB and antiretroviral therapy (ART).
Design and methods:
We prospectively evaluated T-cell immunophenotypes by flow cytometry and cytokines by Luminex assays in a subset (n ¼ 154) of highly immunosuppressed HIV-infected patients with TB from the Cambodian Early versus Late Introduction of Antiretrovirals randomized clinical trial. We compared findings from patients who developed TB-IRIS with findings from patients who did not develop TB-IRIS. Data were evaluated with mixed-effect linear regression, Kaplan-Meier estimates, and Wilcoxon rank-sum tests, and q-values were calculated to control for multiple comparisons.
Results: Development of TB-IRIS was associated with significantly greater pre-ART frequencies of HLA-
þ , and Fas þ effector memory CD8 þ T cells, and significantly elevated levels of plasma interleukin (IL)-6, IL-1b, IL-8, and IL-10, and viral load. Post-ART initiation, effector memory CD4 þ and Fas þ effector memory CD4 þ T-cell frequencies significantly expanded, and central memory CD4
þ T-cell frequencies significantly contracted in patients who experienced TB-IRIS. By week 34 post-TB treatment initiation, effector memory/central memory CD4 þ T-cell ratios were markedly higher in TB-IRIS versus non-TB-IRIS patients.
Conclusions: A distinct pattern of pre-ART T-cell and cytokine markers appear to poise the immune response of certain patients to develop TB-IRIS. Experience of TB-IRIS is then associated with long-term remodeling of the CD4 þ T-cell memory compartment towards an effector memory-dominated phenotype. We speculate that these pre and
Introduction
When antiretroviral therapy (ART) is initiated in rapid succession to tuberculosis (TB) therapy in HIV/TB coinfected patients, risk of immune reconstitution inflammatory syndrome (IRIS) increases [1] [2] [3] [4] . Typically, TB-IRIS occurs after the start of TB therapy and after initial improvement of TB symptoms [5] , and is characterized by clinical deterioration after ART initiation that manifests in fever, enlarged lymph nodes, and radiological features of TB disease not associated with treatment failure due to mycobacterial resistance, poor adherence to the treatment regimen, or another opportunistic infection [5, 6] .
The Cambodian Early versus Late Introduction of Antiretrovirals (CAMELIA) randomized clinical trial (ANRS1295/CIPRA KH001) demonstrated that initiation of ART at 2 weeks (early arm) as compared to 8 weeks (late arm) after TB treatment initiation significantly decreased mortality by 34% in highly immunocompromised HIV-positive adults (median CD4 þ T-cell count 25 cells/ml) with newly diagnosed TB [1, 7] . Early ART was also associated with a significantly increased risk (2.5-fold) of TB-IRIS in the CAMELIA study [1, 7] . Notably, the survival benefit of early ART in CAMELIA was observed up to 3 years after the earlier ART timing intervention [1, 7] .
To investigate immunological recovery in TB/HIV patients and the mechanisms underlying TB-IRIS, we nested a prospective sub-study [Cambodian Paradoxical Reaction Immune Study-T cells or 'CAPRI-T' (ANRS 12164)] within the CAMELIA trial. We enrolled patients from both treatment arms at the time of their entry into the CAMELIA trial and performed extensive immunophenotypic and cytokine profiling on patient samples after TB treatment initiation (prior to the start of ART), and at several time-points post-ART initiation up to 34 weeks after the start of TB treatment.
Methods
Study population, design, implementation, and oversight The CAMELIA trial was a prospective, multicenter, open-label superiority trial conducted in Cambodia that enrolled HIV-positive adults with a CD4 þ T-cell count 200/ml or less and newly diagnosed TB as confirmed by any clinical sample that was smear-positive for acid-fast bacilli (AFB) [1] . Patients were randomly enrolled in the CAPRI-T sub-study from both arms of the CAMELIA trial after enrollment in the CAMELIA trial (Fig. 1a) . After written informed consent was provided, 10 ml of blood was drawn at the time-points shown in Fig. 1b . CD4
þ T-cell counts and HIV viral loads were determined at the Institut Pasteur in Cambodia as described [1] . Pre-ART clinical characteristics were taken from the CAMELIA database. See Supplementary Data for additional details (http://links.lww.com/QAD/A617).
Characterization of TB-IRIS
Characterization of TB-IRIS was a secondary objective of the CAMELIA trial and has been described elsewhere [1, 7] . See Supplementary Data for details (http://links. lww.com/QAD/A617).
Ethics statement
The CAPRI-T and CAMELIA study protocols and consent forms were approved by the National Ethics Committee of Cambodia, the NIH (CSRC), and institutional review boards of the Institut Pasteur, France, and the Immune Disease Institute (now the Program in Cellular and Molecular Medicine, Children's Hospital) of Boston, Massachusetts, USA. All work was conducted according to the principles expressed in the Declaration of Helsinki.
T-cell immunophenotyping
Phenotypic studies were performed on freshly isolated whole blood. After staining with antibodies, cells were processed by standard lyze/wash procedure and acquired on a four-color BD FACScalibur II cytometer (BD, Paris, France) on site at the Institut Pasteur in Cambodia. All flow cytometry data were analyzed using Flow-Jo 8.8.4 software (FLOWJO, LLC, Ashland, Oregon, USA). Lymphocytes gated by light scattering were verified to be more than 90% pure using standard CD14/CD45 back-gating methods [8] , and samples were excluded if this threshold was not met. Panels of antibody conjugates used for staining are shown in Supplementary Table 1 (http://links.lww.com/QAD/A617), and a representative example of gating strategy is shown in Supplementary  Fig. 1 (http://links.lww.com/QAD/A617).
Statistics
Mixed-effect linear regression was used to characterize progression of the phenotypic markers under ART, with time 0 being ART initiation; the effects of TB-IRIS and of the early or late arm on both phenotype frequency at ART initiation and changes in its progression were investigated. Phenotypic markers were first checked for normal distribution using Kernel density plots, and a square root transformation was used when the distribution was not normal. Association of specific phenotypes with the risk of occurrence of TB-IRIS was described using KaplanMeier estimates after stratifying by phenotype frequency ( versus > median at ART initiation) and after comparison between groups was done by log-rank test.
Statistical analyses were performed using the Stata 11 (Stata Corporation, College Station, Texas, USA) and the false discovery rate (FDR) correction [9] was performed using the R software (R Foundation for Statistical Computing, Vienna, Austria; http://www.R-project.org).
Results
Impact of timing of antiretroviral therapy, viral load and CD4 R T-cell count on TB-IRIS Of the 154 patients included in the CAPRI-T study, 50 developed clinically validated TB-IRIS secondary to TB treatment and ART initiation (Fig. 1a) . We note that all other potential causes of IRIS (apart from TB) were ruled out (Supplementary data, http://links.lww.com/QAD/ A617) [1, 7] . None of the 104 non-TB-IRIS patients exhibited signs or symptoms of TB-IRIS at any time during their clinical course. TB-IRIS occurred at a median of 12 days [interquartile range (IQR) 7-24] post-ART initiation and occurred at similar times post-ART in both CAMELIA treatment arms (median of 11.5 and 16 days, respectively; P ¼ 0.27). TB-IRIS was significantly more common in the early (34/80; 42%) versus late (16/74; 22%) (P ¼ 0.003) treatment arm, consistent with findings in the overall CAMELIA cohort [1, 7] .
At ART initiation, the CD4 þ T-cell count in TB-IRIS patients and non-TB-IRIS patients was similar [median 22 cells/ml (IQR 11-52) and 32 cells/ml (IQR 15-71), respectively; P ¼ 0.10], as was BMI [median 17.6 (IQR [16] [17] [18] [19] and median 17.8 (IQR [16] [17] [18] [19] [20] , respectively; P ¼ 0.88]. However, pre-ART viral load was significantly higher in TB-IRIS patients versus non-TB-IRIS patients [median 5.9 (IQR 5.4-6.4) versus 5.6 (IQR 5.2-6.1) log copies/ml, respectively; P ¼ 0.04]. Other baseline characteristics of TB-IRIS and non-TB-IRIS patients in the CAPRI-T study were similar, consistent with the overall CAMELIA cohort (Supplementary Table 6 , http://links. lww.com/QAD/A617) [7] .
TB-IRIS and activated and regulatory T cells
Prior to ART initiation, patients who went on to develop TB-IRIS had a significantly greater frequency of activated (CD45RO
þ T cells compared to non-TB-IRIS patients (P < 0.0001) (Fig. 2a) . This subset of cells remained significantly higher in the TB-IRIS group at week 34 post-TB therapy initiation (P ¼ 0.0003), which was week 32 and week 26 post-ART in the early and late CAMELIA treatment arms, respectively (Fig. 1b) . Before ART, TB-IRIS patients also had significantly higher proportions of CCR5 (Fig. 2b) , which remained markedly higher at week 34 relative to the non-TB-IRIS group (P < 0.0001) (Fig. 2b) . By contrast, proportions of activated CD8
T cells at the start of ARTwere not significantly different in the two groups (P ¼ 0.91), although there was a greater post-ART decrease in activated CD8
þ T-cell frequency in non-TB-IRIS patients (P ¼ 0.041; Fig. 2c ).
To determine whether regulatory CD4
þ T-cell (CD4 þ Treg) frequencies differed between TB-IRIS and non-TB-IRIS patients, we employed surface staining to enumerate CD25
þ Treg frequencies were similar in the two groups prior to ART initiation (P ¼ 0.72; Fig. 2d ). However, patients who experienced TB-IRIS exhibited a much greater post-ART rate of decline in CD4
þ Treg frequency (P < 0.0001), resulting in a significantly lower proportion of CD4 þ Tregs in TB-IRIS patients as compared to non-TB-IRIS patients at week 34 post-TB therapy initiation (P ¼ 0.034) (Fig. 2d) .
TB-IRIS and T-cell memory
To evaluate the impact of TB-IRIS on the reconstitution of antigen-experienced T-cell subsets, we next studied changes in effector memory and central memory CD4 þ T-cell proportions and their association with TB-IRIS. At ART initiation, there was no appreciable difference between effector memory (CD62L
þ T-cell frequencies in patients who did or did not develop TB-IRIS (P ¼ 0.96 and P ¼ 0.48, respectively) ( Fig. 3a  and b) . Strikingly, however, effector memory and central memory CD4
þ T-cell frequencies diverged significantly in the two patient groups after ART initiation. The effector memory CD4 þ T-cell frequency rose, and the central memory CD4
þ T-cell frequency declined, at significantly greater rates in TB-IRIS patients (P ¼ 0.001 and P ¼ 0.004, respectively), and by week 34, TB-IRIS patients had significantly higher effector memory CD4 þ T-cell proportions (P ¼ 0.002) and significantly lower central memory CD4
þ T-cell proportions (P ¼ 0.011) ( Fig. 3a and b) .
The frequency of Fas
þ effector memory cells, was also similar in non-TB-IRIS and TB-IRIS patients at ART initiation (P ¼ 0.40). Post-ART, however, the frequency of Fas þ effector memory CD4
þ T cells rose significantly in TB-IRIS patients (P ¼ 0.005) and at week 34 was markedly higher in this group (P ¼ 0.003) (Fig. 3c) .
By contrast, the proportion of Fas
þ T cells was significantly higher in TB-IRIS patients at ART initiation (P < 0.0001; Fig. 3d ), although the overall effector memory CD8
þ T-cell frequency was similar between the groups at week 0 (P ¼ 0.06). Furthermore, the proportion of CD8 þ T cells with a central memory/early effector memory or 'transitional' phenotype [13] [14] [15] (CD27 þ CD45RA À ) was significantly lower in TB-IRIS patients (P ¼ 0.017) (Fig. 3f) . By week 34, however, there were no differences between TB-IRIS and non-TB-IRIS patients in proportions of Fasþ effector memory CD8
TB-IRIS and T-cell co-stimulatory signals
We next evaluated a panel of CD4 þ or CD8 þ costimulatory markers. We found no differences in proportions of ICOS Supplementary Tables 2  and 3 , http://links.lww.com/QAD/A617 for full list of P and q values). up arrow, higher in TB-IRIS; down arrow, lower in TB-IRIS. For CCR5 þ CD4 þ T cells and CD4 þ Tregs, regression plots were generated with square root transformation due to proportions were significantly elevated (P ¼ 0.013) at ART initiation in TB-IRIS relative to non-TB-IRIS patients (Fig. 4a) , and post-ART, this cellular subpopulation declined to a much greater extent in the TB-IRIS group (P < 0.0001). leading to similar OX40 þ CD4 þ T-cell frequencies in the two groups (P ¼ 0.15) at week 34.
When we divided the 154 patients into two groups based on median OX40
þ CD4 þ T-cell frequency at ART initiation (median 7.4%), Kaplan-Meier analysis revealed that a pre-ART OX40 þ
CD4
þ T-cell frequency greater than 7.4% was associated with a significantly greater risk of developing TB-IRIS as compared to a frequency 7.4% or less (P ¼ 0.036) [hazard ratio 1.8, 95% confidence interval (CI) 1.03-3.36] (Fig. 4b) . We note that no other cellular phenotype was associated with TB-IRIS risk after similar stratification by median pre-ART phenotype frequency.
Cellular and cytokine changes between antiretroviral therapy initiation and TB-IRIS In order to evaluate early post-ART immune parameters associated with development of TB-IRIS, we evaluated changes from week 0 of ART to the time of TB-IRIS in a randomly selected subgroup of TB-IRIS patients (n ¼ 32) who experienced TB-IRIS within 3 weeks (median of 10 days, IQR 6-14) post-ART. As controls, we evaluated the same parameters in a randomly selected subgroup (n ¼ 28) of non-TB-IRIS patients who had a week 2 post-ART time-point available (see Supplementary data, http://links.lww.com/QAD/A617). The net increase in CD4 þ T-cell frequency was similar between the two groups (Fig. 5a) ; however, the net T-cell frequencies from ART initiation to the TB-IRIS time-point was significantly greater (P ¼ 0.0023 and P ¼ 0.0035, respectively) than to the 2-week post-ART time-point in non-TB-IRIS patients (Fig. 5b and c) . No differences in activated CD8 þ and CD4 þ Treg frequency increases were detected ( Fig. 5d and e We also measured plasma levels of 12 different cytokines by Luminex, which revealed that the net increases in IL-6 and IL-1b were significantly greater at the TB-IRIS event than at the 2-week post-ART time-point in non-TB patients (IL-6: P ¼ 0.0066 and IL-1b: P ¼ 0.026; Fig. 5f and g ). Other cytokine differences included: IL1b, IL-6, IL-8, and IL-10 higher prior to ART and at the TB-IRIS time-point; IL-17, IL-12, and TNF similar at ART initiation, but higher at the time of TB-IRIS; and IL-2, IL-7, GM-CSF, and IFN-g similar at all time-points ( Supplementary Fig. 3 , http://links.lww.com/QAD/ A617 and Supplementary Data, http://links.lww.com/ QAD/A617).
Discussion
We have identified distinct immunological patterns that differentiate TB-IRIS and non-TB-IRIS patients both prior to ART and post-ART. Pre-ART, significantly higher frequencies of cellular subsets associated with T-cell activation, including HLA-DR
þ , and OX40 þ CD4 þ T cells and Fas þ effector memory CD8 þ T cells were associated with TB-IRIS. Furthermore, prior to ART initiation, higher viral loads and significantly elevated levels of circulating IL-1b, IL-6, IL-8, and IL-10 were present in patients who developed TB-IRIS. Post-ART, effector memory CD4 þ T cells and Fas þ effector memory CD4 þ T cells increased, and central memory CD4
þ T cells decreased in TB-IRIS patients relative to non-TB-IRIS patients, and these differences remained evident even 2 months after completion of TB treatment and over 4 months after the vast majority of TB-IRIS events.
Our ability to detect previously unidentified immunological parameters associated with risk of TB-IRIS, TB-IRIS pathogenesis, and post-TB-IRIS immune reconstitution was facilitated by our study design. The nesting of the prospective CAPRI-T study within the CAMELIA trial provided strategic advantages over other studies that were observational or retrospective in nature, including: the ability to prospectively evaluate patients who went on to develop TB-IRIS and 'control' patients who avoided TB-IRIS from a single large cohort of treatment-naive patients of similar ethnicity, all with profound HIV-associated immunosuppression and newly diagnosed AFB smear-positive TB; clinical TB-IRIS Tables 2 and 3 , http://links.lww.com/QAD/A617 for full list of P and q values). Up arrow,higher in TB-IRIS; down arrow, lower in TB-IRIS. Since OX40 þ CD4 þ T-cell frequencies were not normally distributed, they were plotted using square root transformation. So the spread of values in each subgroup (TB-IRIS versus non-TB-IRIS) can be better appreciated, the two patient groups are shown immediately adjacent to one another at weeks 0, 2, 6, 8, 26, and 32 post-ART in Supplementary Fig. 6 , http://links.lww.com/QAD/A617. (b) Plot depicting Kaplan-Meier estimates for probability of developing TB-IRIS depending on pre-ART frequency of OX40 þ CD4 þ T cells. Black line: patients with more than 7.4% OX40 þ CD4 þ T cells at ART initiation; gray line: patients with 7.4% or less OX40 þ CD4 þ T cells at ART initiation. ART, antiretroviral therapy; IRIS, immune reconstitution inflammatory syndrome; TB, tuberculosis.
validation or exclusion by an experienced clinical team; and the sampling design, which included long-term follow-up, allowing us to evaluate the impact of TB-IRIS on ART-mediated T-cell reconstitution.
Previous studies have reported increased global CD4
þ Tcell activation at the time of, or following, TB-IRIS [16, 17] , or during IRIS precipitated by diverse opportunistic infections [18] . This is the first study, however, to demonstrate that activated CD4 þ T-cell frequencies are elevated prior to ART in TBþ/HIVþ patients who go on to develop TB-IRIS. Furthermore, this pre-ART CD4 þ T-cell activation was accompanied by a significantly higher OX40 þ
CD4
þ T-cell frequency, and this latter phenotype was predictive of TB-IRIS risk. We also found that the activated CD4 þ T-cell frequency increases more dramatically post-ART in the TB-IRIS group, confirming a previous study [17] . Taken together, these findings underscore the critical role of CD4 þ T cells in the development of TB-IRIS, and clearly demonstrate that the pre-ART CD4 þ T-cell compartment is distinct in the subset of TB þ /HIV þ patients who subsequently develop TB-IRIS. In agreement with other studies [17, 19, 20] , pre-ART CD4
þ Treg proportions were similar in both TB-IRIS and non-TB-IRIS patients, although there was a relatively greater post-ART decline in this CD4 þ subpopulation in TB-IRIS patients.
Our finding that an elevated pre-ART CCR5
T-cell frequency was also associated with TB-IRIS development, combined with the relatively higher pre-ART viral loads in TB-IRIS patients, provides a novel link between pre-ART CCR5 þ CD4 þ T-cell levels, viral load, and TB-IRIS occurrence. Although a recent small study reported that CCR5 þ
þ T-cell proportions were higher in TB-IRIS versus non-TB-IRIS patients at week 6 post-ART [21] , only seven TB-IRIS patients were analyzed, and there was no indication when TB-IRIS occurred in these patients relative to ART initiation. In our patient cohort, which included 50 TB-IRIS patients, we found that the already elevated CCR5 þ
þ T-cell proportions increased dramatically further in the 2 weeks post-ART relative to non-TB-IRIS patients, and remained significantly higher 6 months later. CCR5 is a critical homing receptor for Th1 cells to 
þ regulatory T cells; (f) plasma IL-6; and (g) plasma IL-1b. ART, antiretroviral therapy; IL, interleukin; IRIS, immune reconstitution inflammatory syndrome; TB, tuberculosis.
peripheral inflammatory sites, including the lungs and the central nervous system [22] [23] [24] [25] . Thus, the rapid post-ART increase in CCR5 þ
þ T-cell frequency in TB-IRIS patients may help explain certain clinical manifestations of TB-IRIS, including pleural effusion and neurological symptoms [4, 7, 26, 27] . In addition, since CCR5 is a major co-receptor for HIV [28] , the higher pre-ART CCR5 þ CD4 þ T-cell frequency in patients who develop TB-IRIS may help drive the higher viral loads observed in these patients.
Although other innate immune cell types, including natural killer (NK) cells and g/d T cells, have been linked to TB-IRIS development [16, 29] , it is becoming increasingly clear that myeloid cells also play a major part in this syndrome [30] . Our finding that plasma IL-1b levels are elevated pre-ART and increase significantly post-ART initiation in TB-IRIS patients relative to non-TB-IRIS patients provides the first clear indication that this critical pro-inflammatory mediator plays a role in TB-IRIS. We also found that circulating IL-6 levels were higher prior to ART in the TB-IRIS group and increased more dramatically in the TB-IRIS patients once ART began. Furthermore, plasma IL-8, IL-12, and TNF (which is also produced by activated T cells [31] ) levels were all significantly higher at the time of TB-IRIS, confirming previous reports that found higher plasma levels of these pro-inflammatory mediators prior to ART and/or at the time of TB-IRIS [32] [33] [34] [35] [36] [37] [38] [39] .
Although other studies have found elevated Mycobacterium tuberculosis (MTb) antigen-induced IFN-g production by T cells from TB-IRIS patients stimulated ex vivo [16, 17, 21, [40] [41] [42] [43] , and higher levels of IFN-g in plasma of TB-IRIS patients [40] , we saw no difference in plasma IFN-g levels between TB-IRIS and non-TB-IRIS patients. We did observe that circulating IL-10 levels were significantly higher in TB-IRIS patients both pre-ART and at the time of TB-IRIS, similar to what was observed in a South African patient cohort [40, 44] . Thus, the relatively elevated IL-10 levels in the TB-IRIS group might have suppressed IFN-g production.
Our findings that elevated CCR5
þ CD4 þ and OX40 þ CD4 þ T-cell frequencies, and circulating IL-1b and IL-6 levels, are present pre-ART in patients who go on to develop TB-IRIS point to possible therapeutic interventions to reduce TB-IRIS incidence and/or severe or complicated clinical presentations of TB-IRIS. Although the recently completed CADIRIS trial found no benefit from inclusion of the CCR5 blocker maraviroc at ART initiation in reducing IRIS incidence due to multiple causes, the patients included in this trial had CD4 þ cell counts above 100 cells/ml and viral loads as low 10 3 copies/ml [45] . It is possible, therefore, that CCR5 antagonists would have some benefit in patients with more advanced immunosuppression and higher pre-ART CCR5 þ CD4 þ T-cell frequencies, like those analyzed here. We note that IL-1b and IL-6 antagonists are also in clinical use for diverse inflammatory conditions [46] , and OX40/OX40L antagonists are currently in development [47] .
TB-IRIS incidence was significantly higher in CAPRI-T patients from the early treatment arm (ART at 2 weeks post-TB treatment) versus the late treatment arm (ART at 8 weeks post-TB treatment), as it was in the overall CAMELIA cohort [1, 7] . We imagine that the steep post-ART rise in effector memory/central memory CD4 þ T-cell ratio in the TB-IRIS group, which was especially apparent after week 8 when the vast majority of TB-IRIS cases had resolved, reflected an MTb-specific response, and that this response was amplified in the early treatment arm. In this scenario, early ART would be expected to facilitate the expansion of MTb-specific CD4 þ T-cell clones in patients who were already predisposed to respond strongly to TB infection once immune reconstitution began, which may have been enhanced by relatively higher bacterial burden at the time of early ART initiation. By contrast, delay of ART to 8 weeks in patients with a similarly 'primed' CD4 þ T-cell compartment may have led to a more muted and less robust MTbspecific response due to the relatively lower bacterial burden by this time-point, and the greater CD4 þ T-cell functional impairment due to the absence of ART for six additional weeks in the context of very high viremia.
Due to our study design we could evaluate the impact of TB-IRIS on ART-mediated T-cell reconstitution up to two months after TB therapy completion/TB cure. Here, we have shown that effector memory and Fas þ effector memory CD4 þ T-cell frequencies expanded, and central memory CD4
þ T-cell frequencies contracted, at significantly greater rates post-ART in TB-IRIS patients versus non-TB-IRIS patients, up to week 34 post-ART. This strongly suggests that the TB-IRIS event is associated with a dramatic and long lasting shift in effector memory/ central memory CD4 þ T-cell ratios. Our findings differ from a previous retrospective study of patients with IRIS caused by diverse opportunistic pathogens, which found similar kinetics of effector memory CD4 þ T-cell expansion/contraction between IRIS and non-IRIS patients post-ART [18] . Intriguingly, effector memory CD4 þ T cells are elevated in individuals with latent TB as compared to Bacillus Calmette-Guerin (BCG)-vaccinated individuals, consistent with this memory subpopulation playing a critical role in the long-term control of TB reactivation [48] . Indeed, it has been argued that induction of 'frontline' effector memory T cells that can respond to pathogens that establish chronic infections at sites of entry (like the lung for MTb) should be a major goal of HIV, malaria, and TB vaccines [49] .
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